Table of Contents

doi : 10.1016/S0923-7534(25)00175-9

Volume 36, Issue 6, June 2025, Pages i-ii

Buy The Package and View The Article Online

Editorial Board

doi : 10.1016/S0923-7534(25)00176-0

Buy The Package and View The Article Online

Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody–drug conjugates arrived?

doi : 10.1016/j.annonc.2025.03.022

Buy The Package and View The Article Online

Liquid biopsy in gliomas—are we there yet?

doi : 10.1016/j.annonc.2025.03.017

Buy The Package and View The Article Online

Advancing circulating tumor DNA detection: using whole-genome sequencing to power minimal residual disease monitoring in breast cancer

doi : 10.1016/j.annonc.2025.03.008

Buy The Package and View The Article Online

Challenges and opportunities of emerging mechanisms of resistance to KRASG12C inhibitors

doi : 10.1016/j.annonc.2025.03.009

Buy The Package and View The Article Online

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice

doi : 10.1016/j.annonc.2025.02.009

Buy The Package and View The Article Online

Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆

doi : 10.1016/j.annonc.2025.01.023

Buy The Package and View The Article Online

Redefining clinical trial strategic design to support drug approval in medical oncology

doi : 10.1016/j.annonc.2025.03.005

Buy The Package and View The Article Online

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

doi : 10.1016/j.annonc.2025.02.011

Buy The Package and View The Article Online

ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma☆

doi : 10.1016/j.annonc.2025.02.005

Buy The Package and View The Article Online

Whole genome sequencing-powered ctDNA sequencing for breast cancer detection

doi : 10.1016/j.annonc.2025.01.021

Buy The Package and View The Article Online

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors

doi : 10.1016/j.annonc.2025.01.020

Buy The Package and View The Article Online

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

doi : 10.1016/j.annonc.2025.03.002

Buy The Package and View The Article Online

Letter to the Editor—Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials

doi : 10.1016/j.annonc.2025.03.003

Buy The Package and View The Article Online

Reply to the Letter to the Editor by Perez et al. regarding “Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials�

doi : 10.1016/j.annonc.2025.03.004

Buy The Package and View The Article Online

Advanced cancer: a robust surrogate of cancer mortality in early detection trials?

doi : 10.1016/j.annonc.2025.03.001

Buy The Package and View The Article Online

Corrigendum to “Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma�: [Annals of Oncology 30 (2019):990-997]

doi : 10.1016/j.annonc.2025.03.020

Buy The Package and View The Article Online